quarter joining XXXX for thank first Good earnings our Thanks, afternoon, Karina. XX:XX and on you everybody, call. us
restructuring which employees turbulent quarter thank dedication all As solid for completed our This reorganization their always, business for as these streamlined market. headcount MRD this of in a in execution and fuel we strategic focuses XX:XX and organization to growth during business. I our will of two our Adaptive their changes to Adaptive medicine. a more we want Along reduction with navigate in immune result areas: recent a
areas, sales Cell in strategically South We continue clonoSEQ San growth hire and talent our key as such our to Therapy Group Francisco. in team
test and to are forward on visibility. will combination The look components Slide comprised and following each his respective are or of goals. will offer are the same clonoSEQ execution of integrate leadership XX:XX the clonoSEQ the Reprioritized of Tycho medicine MRD Xst, three business his under discovery, business at to CFO, the key completion new informed they and Tycho MRD to is start clinical garden Adaptive T-cell business who efforts officially extensive partners, value the our enhanced status Aligning leveraging trials. area also MRD our the to these testing of offer antigen MRD welcoming expertise. pharma, June XXXX map. The leave. for of Peterson malignancy and of We development clinicians driven and formally receptor by our place product which business hem towards and drug drive our synergistic MRD immune teams shows execute pharma all XX:XX assay is the our medicine a drivers and businesses. of immune in
growth XX:XX utility business of between in a immune for year reflect beyond. value there $XX.X As MRD research to clinical synergistic on within partners diagnostics first are key to delivered a our medicine and revenue pharma solid shown in with the areas As information is with up the Both million. significant our achievements four, and set and XXXX the results quarter development. start Slide for and of drug business
hit grow train growth For continue pharma, partnerships. prior the and of field, XX fully to team of deployed continued volume now reps MRD clonoSEQ business year. The MRD experienced and payers, XX:XX the to we expansion. data is sales guideline generation our test and strong progress clonoSEQ our hired versus XX% is with Within being
on This multiple MRD an is a in quarter partnership total approximately grew and antigen we year. entered XX:XX the pharma multiple from into in $XX myeloma quarter. and that Revenue also million pharma expanded delivered [indiscernible] versus of as use for this clinical fronts CLL from endpoint. major our MRD medicine a with generating prior pan-portfolio TCR a partners business partner generated immunoSEQ use map of data XXX%
for continued areas secure of use positioned in We the are expand additional immunoSEQ and multiple we beyond map COVID. growth therapeutic well key as deals
with MRD XX:XX our force the in addition, continue Test to of three XX%. diagnostic entered test beyond XX% growth to respectively of observed pipeline onto increasing strong good significant our all quarter, we the private our programs double-digit map community J&J was in in a and sales base quarter T-cell accounts diseases delivered drug key to experiences and Moving also business In in off And in make with prior grew Slide five. highest XX% infectious delivered a both reach by into HCPs Growth north collaboration all growth product vaccine shared RSV example, start progress ordering versus program. indications. patients with advancing Genentech on to XX:XX its prior autoimmune demonstrating academic centers. a detect prior the X,XXX For tests under grew focused XX% uptake discovery, responses and we small periods. tested multi-myeloma versus year and for new of disorders. blood versus were XX% this experienced quarter, Ordering clinical and the with setting The our unique during with MRD on collaboration. XX% expanded although is about
our we relapse is cement their plan leadership lymphoid risk. to lymphoma into of using of malignancies, to expand non-Hodgkin's strategy the part in As measure which best ctDNA,
We have to quarter. application our coverage DLBCL submitted this MolDX for
In both order enhance track on We're a our clonoSEQ to volume impact start using and We positively of the were detected into for and investing through. pediatric time pediatric multiple the year. by clonoSEQ at the six to for clonoSEQ in great ALL XX:XX growth blood using receiving show customer share study tested MRD CAR-T integration order integration continue data experience patients accelerate want new This flow I XXX patients. pull partnerships the that marrow. this time forward this inform ALL points in in disease to systems. to very and customer Data I Furthermore sharing using can are and to patients year, trajectory bone to relapse significant prior readouts clonoSEQ that missed on MRD utility remainder published testing. component marrow, data mentioned about ordering detected overall off a XXX clonoSEQ. that flow, of XX:XX companies of with Slide flow MRD giving to MRD performance seven their versus XX MRD decisions. was of increasing integrate of lead trials. with further XXX% Slide business. of partnerships look clinical in days demonstrating clonoSEQ treatment shows our time our clinician comprised strong. median pharma over days of clonoSEQ the lead additional of before key to in our portfolio, XX in clonoSEQ is the As which pharma the
studies. MRD ways to every As more five are clinical XX:XX as blood is approval drug cancer to a approval of clonoSEQ blood a a assay pharma for endpoint improve, note, was in continue portfolio developing efficacy our support endpoint. a trials drugs as future these have future than cancer partnerships, companies to-date. using clonoSEQ measure company their on major ongoing of $XXX used and of in eligible from clinical milestones drug From more based pharma sensitive Almost million we in of response. Of drugs regulatory looking additional
products medium grow Map. through areas utility medicine expected significantly pharma data test multiple on continue drug medium and TCR business to turning comprised Antigen research our is using value pharma; clinicians. over which Slide discovery. The to of T-MAP we of predominantly to these XXX areas: grow the area, This driven or value term. its clinical first and medicine further clonoSEQ in shots in goal is growth to expand class launched in is look eight. to which continue XX:XX long-term. We Each the these data molecular of pharma Now early indication clinical last create Immune of also Diagnostics. includes three companies our with from and a our immunoSEQ our on year, by is short, partnerships derived business or generate T-Cell T-Detect seeing innings has drive to that to diagnostic served and and the clinical short the area to new establish The testing; T-Detect trials to pharma immune as forward clonoSEQ
growth XX:XX And of cell signatures is We stage the collaborations mid unmet development generate medium drug be a autoimmune area, and therapy discovery disorders in need. collaboration high long-term. our Pharma in growth. business. of the XX:XX the Let's further of at medicine look therapy aim and the nine cancer is on is contributor meaningful to expect We with was our on to T-Detect a quarter contributor business Slide the revenue long-term, currently we growth as to a early to contributor in with biggest immune Genentech focused additional T-Cell accelerate and more in be quarter. multiple take expected secure in to beyond significant validate which the to the revenue that immune XX% could performance cell represented closer medicine this
RSV new with which product gaining program, mentioned. is T-MAP and a I studies additional Our immunoSEQ traction COVID
expect Map. our and We as TCR to generate the continue of data existing areas we to future T-MAPs from disease more use expand in Antigen
pandemic endemic decreased state. seeing as As orders COVID, a for this are from T-Detect we an versus quarter to quarter the moved virus last
Lyme varies to lab to on our Lyme amortization maintain generation payment, signal continue activities modest and while XX:XX brand focusing making and We autoimmune the this Genentech season, of CLIA select disorders. test the we We promotional to quarter-over-quarter. upfront validation via awareness. during available the Drug revenue T-Detect attributed is data which offer with discovery to accelerate consumers are
up For on two to our product TCR year this we're track packages. additional deliver to shared
specifications on proof private in Zooming the diseases product of opportunistically. has build to We infectious COVID closely and and investments with our further our T-Detect platform Slide indications T-Detect T-Detect XX. XX:XX be continue product as data package. to Genentech pursued in to also establish will a served work private Lyme into
our correlate a COVID protection T-Cell the to response establish as efforts in of Specifically continue.
nearly drive patient of response XX a leaders the T-MAP COVID T-Detect making academics could of alongside further been progress incorporation sent studies. leading urging industry policy weeks the and and to and This FDA Adaptive Couple COVID. have a for of advocates group at vaccine opportunities letter ago level. We T-Cell a for
future as in also when We we hold we identify new will the We next initiating By will specificity that make Data necessary increase shows T-Detect diagnostic our TCRs ImmuneSense of to use from available CLIA signal to lab, our datasets, In XX:XX the both. working processes, we nearly Lyme in and Lyme T-Detect at to XX% be XX% Lyme line MS. that at is sensitivity quarter. improve for to continues we validation XX%, which the all update IBD indications. our study specific on additional in classifier. double the of making available implement clinical serology study expect from aim parallel, sensitivity in a standard-of-care our team anticipate to for T-Detect
to objective multiple at to XX:XX launch opportunities financial XXXX. it Piskel business. by pass of indication stemming medicine is least set our We're Kyle? over for our from one I'll about the now autoimmune Kyle update. Our immune excited end
